Research on cell sources for brain cell replacement methods has gained major importance. Cell and gene therapy are potentially intriguing new domains of regenerative medicine

Great advances in neurodegenerative disease, cell and gene therapy have been made in recent decades. Following the recent advancement of stem cell-based neuronal therapies, including managing their differentiation potential, research on cell sources for brain cell replacement methods has gained major importance. The objective is to obtain a certain neuronal cell fate to repair and restore the injured cell function. Several cell-based therapeutic techniques that show promise in animal HD models have failed to attain a similar degree of success in human patients. Despite its poor prospects, fetal transplantation has opened the door to a potentially intriguing new domain of regenerative medicine. However, many obstacles need to be overcome before pre-differentiated stem cells can be used in clinical trials, and, in particular, ensuring that the source of stem cells has optimal differentiation potential with full integration and functional enhancement, has measurable clinical benefits with minimal impact on the host immune system, and is tumor-free. New cell, molecular, and pharmacological approaches may assist enhance neuronal survival of transplanted cells, and consequently therapy for many fatal brain diseases. Molecular approaches, on the other hand, have looked into the idea of entirely eliminating HTT utilizing RNAi in the hopes of preventing the mutant protein that produced it in the first place. In contrast, HTT's physiological significance requires the application of procedures that specifically interfere with MHTHTT. The CRISPR/Cas9 approach gives researchers the ability to inactivate the mHTT allele by deleting or editing particular regions, leading to increased knowledge of how to prevent mutation-induced toxicity. Overall, despite their appealing ability to reverse mHTT-induced toxicity, these therapies may face difficulties due to the need to modify their design for individuals in order to ensure therapeutic safety.As clinical investigations are planned, genome editing already shows promise as a potent treatment to overcome clinical HD features. While there is no certainty that HD symptomatology can be fully eased, researchers must continue to hunt for ways to diminish it because it has such profound and life-threatening effects on patients and their families. These new treatments are supposed to bring a brighter future for HD sufferers.